; or (B) the shortage of which would pose a significant threat to the United States health care system or at-risk populations; and (3) with respect to drugs selected for inclusion in the database pursuant to paragraph (2), identifying— (A) the location of establishments registered under subsection (b), (c), or (i) of section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 ) involved in the production of active pharmaceutical ingredients and finished dosage forms, and the amount of such ingredients and finished dosage forms produced at each such establishment; (B) to the extent available, the location of establishments so registered involved in the production of the key starting materials and excipients needed to produce the active pharmaceutical ingredients and finished dosage forms, and the amount of such materials and excipients produced at each such establishment; and (C) any regulatory actions with respect to the establishments manufacturing such drugs, including with respect to labeling requirements, registration and listing information required to be submitted under section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 ), inspections and related regulatory activities conducted under section 704 of such Act ( 21 U.S.C. 374 ), the seizure of such a drug pursuant to section 304 of such Act ( 21 U.S.C. 334 ), any recalls of such a drug; inclusion of such a drug on the drug shortage list under section 506E of such Act ( 21 U.S.C. 356e ), or prior drug shortages reports of a discontinuance or interruption in the production of such a drug under 506C of such Act ( 21 U.S.C. 355d ). (b) Report Not later than 18 months after the date of enactment of this Act, and annually thereafter, the Secretary of Health and Human Services, in consultation with the heads of agencies with which such Secretary coordinates under subsection (a), shall submit a report to Congress on— (1) progress on implementing subsection (a), including any timelines for full implementation, if any